Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSIST ASTHMA-2: Felcorekibart in Uncontrolled Asthma
NCT07782996Phase 3Recruiting
- Sponsor
- GSK
- Start
- Aug 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Felcorekibart + Standard of care with Placebo + Standard of care (2 arms). Primary endpoint: Annualized rate of clinically significant asthma exacerbations at 52 weeks. Started Aug 2026; status: recruiting.
02
Drugs
felcorekibart
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07782996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07782996.